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ABSTRACT
Antisense oligonucleotides that are dependent on
RNase H for cleavage and subsequent degradation
of complementary RNA are being developed as ther-
apeutics. Besides the intended RNA target, such
oligonucleotides may also cause degradation of un-
intended RNA off-targets by binding to partially com-
plementary target sites. Here, we characterized the
global effects on the mouse liver transcriptome of
four oligonucleotides designed as gapmers, two tar-
geting Apob and two targeting Pcsk9, all in differ-
ent regions on their respective intended targets.
This study design allowed separation of intended-
and off-target effects on the transcriptome for each
gapmer. Next, we used sequence analysis to iden-
tify possible partially complementary binding sites
among the potential off-targets, and validated these
by measurements of melting temperature and RNase
H-cleavage rates. Generally, our observations were
as expected in that fewer mismatches or bulges in
the gapmer/transcript duplexes resulted in a higher
chance of those duplexes being effective substrates
for RNase H. Follow-up experiments in mice and cells
show, that off-target effects can be mitigated by en-
suring that gapmers have minimal sequence com-
plementarity to any RNA besides the intended target,
and that they do not have exaggerated binding affin-
ity to the intended target.
INTRODUCTION
RNase H is an endonuclease that specifically recognizes
DNA/RNA heteroduplexes and cleaves the RNA strand
(1). The two fragments of the cleaved RNA are not pro-
tected by a 5′-cap or poly-A tail at the cleaved ends, and
are therefore rapidly degraded by endogenous exonucleases
(2). Single-stranded DNA oligonucleotides can be designed
to elicit RNase H-mediated cleavage and subsequent degra-
dation of complementary RNA in cells (3). Such oligonu-
cleotides usually have a gapmer design with chemically
modified flanks conferring improved stability and binding,
and a central DNA gap-region that supports RNase H
binding. A gapmer targeting apolipoprotein B (APOB) was
recently approved for the treatment of homozygous famil-
ial hypercholesterolemia (4), and many others are in clinical
development (5).
It is well-known that gapmers may also cause degrada-
tion of unintended off-targets by binding to partially com-
plementary target sites. Using Xenopus oocytes as a model
system for investigating sequence-specificity of gapmers in
vivo, it was demonstrated more than 20 years ago that gap-
mers can cause degradation of transcripts harboring only
partially complementary target sites (6). More recently, this
observation has also been confirmed for chemically mod-
ified gapmers (7). In fact, for gapmers with high-affinity
modifications, such as locked nucleic acids (LNA) (8) or
constrained ethyl (cEt) nucleosides (9), particular care must
be taken to manage off-target effects (10,11). Generally, un-
intended targeting depends on whether the binding affinity
between gapmer and RNA is sufficient to allow the forma-
tion of appreciable amounts of duplex, and whether RNase
H tolerates the structural changes induced by duplex mis-
matches and bulges. Therefore, in general, as the number of
mismatches and bulges in a partially complementary RNA
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target site increase, the probability of RNase H binding and
cleavage decreases, as has been also shown in cells using li-
brary sequencing (12).
In a therapeutic context, unintended targeting may lead
to unwanted or adverse effects. Indeed, recent experiments
in mice suggest a direct relationship between the effective
reduction in the number of unintended RNA targets in the
liver following administration of high-affinity gapmers and
the hepatotoxic potential of these oligonucleotides, as mea-
sured on the basis of clinical chemistry markers in the blood
(13–16). The hepatotoxic potential of LNA-gapmers can be
evaluated in primary hepatocytes by measurement of LDH
and adenosine triphosphate levels, which allow some con-
trol of this type of toxicity prior to further investigations
in animals (17). More recently, a cellular assay specifically
focused on assessing the hybridization-dependent toxic po-
tential of LNA-gapmers has been suggested. In this ap-
proach, a high concentration of gapmer is transfected into
cells to drive binding and cleavage of all potential off-targets
via mass-action kinetics (18). Potential adverse effects re-
lated to unintended targeting can therefore be managed
both in cells and animals. Nevertheless, there is still a need
for an improved understanding of how to design gapmers
that avoid off-target effects, thereby reducing attrition in
pre-clinical toxicity studies and consequently increasing the
overall chance of developing gapmers with good drug-like
properties.
In this study, we set out first to characterize the extent to
which four different LNA-gapmers bind to and degrade un-
intended RNA targets in the livers of mice after intravenous
injection. We evaluated the global effects on the liver tran-
scriptomes bymicroarray analysis. To separate the effects of
intended and unintended targeting, we designed two gap-
mers targeting the proprotein convertase subtilisin/kexin
type 9 (Pcsk9) transcript in distinct, non-overlapping, re-
gions and two targeting apolipoprotein B (Apob), also in
non-overlapping regions. In this way, the downstream ef-
fects of reducing the intended target transcript levels will
be the same for each pair of gapmers, while any effects
of unintended targeting will be different because of their
completely different sequences. In addition, it has been re-
ported thatPcsk9 is involved in regulatingApobmetabolism
(19), and one of the downstream effects of reducing Apob
mRNA levels is that Pcsk9 mRNA levels are also reduced,
but not vice versa. This experimental design consequently
allows separation of intended and off-target effects, and
identification of sets of transcripts that are significantly and
specifically reduced following treatment with each gapmer.
Follow-up sequence analysis of each set of downregulated
transcripts revealed, as expected, that target regions with
no, or only one or twomismatches or bulges, were identified
more often than expected by chance. Experimental evalua-
tion of the binding affinity and RNase H-cleavage activity
of the potential target regions identified in this manner con-
firmed that transcripts that are significantly and specifically
reduced by gapmer treatment, and which harbor one- or
two mismatches or bulges (but not more), can be substrates
for RNase H.
These results suggest that off-target effects can be miti-
gated by ensuring that gapmers have no- or only a few off-
targets, with less than three mismatches or bulges, and do
not have exaggerated binding affinity beyondwhat is needed
for optimal potencywith respect to the intended target. This
was directly demonstrated in two follow-up experiments.
First, we evaluated the off-target effects in mice of five dif-
ferent gapmers targeting the same intended region and be-
ing of equal length, but having different binding affinities to
the intended target. Second, we evaluated the off-target ef-
fects of four different gapmers in cells, targeting the same in-
tended region and having similar binding affinities and po-
tencies, but being of different lengths and therefore, having
different numbers of mismatches and bulges to off-targets.
Taken together, these results suggest a strategy for design-
ing highly sequence-specific gapmers by optimizing length
and LNA-modification patterns.
MATERIALS AND METHODS
Oligonucleotide synthesis and purification
LNA-modified gapmers were designed with fully modified
phosphorothioate backbones and were synthesized on a
MerMade 192X (Bioautomation, TX, USA) synthesizer
following standard phosphoramidite protocols. The final
5′-dimethoxytrityl (DMT) group was left on the oligonu-
cleotide. After synthesis, the oligonucleotides were cleaved
from the solid support using aqueous ammonia and subse-
quently deprotected at 65◦C for 5 h. The oligonucleotides
were purified by solid phase extraction in TOP DNA car-
tridges (Agilent, Glostrup, Denmark) using the lipophilic
DMT group as a chromatographic retention probe for
purification purposes. After eluting impurities, the DMT
group was removed by treatment with dichloroacetic acid.
As the last step in the purification process, the oligonu-
cleotides were eluted from the cartridge and the eluate was
evaporated to dryness. The oligonucleotides were dissolved
in phosphate-buffered saline (PBS) and the oligonucleotide
concentration in solution determined using Beer–Lambert’s
law by calculating the extinction coefficient and measuring
UV-absorbance. Oligonucleotide identity and purity were
determined by reversed-phase Ultra Performance Liquid
Chromatography coupled to Mass Spectrometry (UPLC-
MS).
Binding affinity of gapmers
Equal amounts of gapmer and RNA were dissolved in
buffer (10 mM phosphate buffer, 100 mM NaCl, 0.1 nM
ethylenediaminetetraacetic acid (EDTA), pH 7.0) to final
concentrations of 1.5mM for each. Samples were denatured
at 95◦C for 3 min and then allowed to anneal by slowly
cooling to room temperature for 30 min. Thermal melting
curves were recorded at 260 nm on a Lambda 40 UV/VIS
Spectrophotometer equipped with a PTP6 Peltier Temper-
ature Programmer (Perkin Elmer, Waltham, USA) using a
temperature gradient that was increased by 1◦C/min from
20◦C to 95◦C and then decreased to 58◦C. First derivatives
and the local maxima of both the melting and annealing
were used to assess the duplex melting temperature (Tm),
defined as the temperature at which half of the gapmers are
duplexed with RNA.
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Gapmer-mediated cleavage of RNA by human recombinant
RNase H1
Gapmer (15 pmol) and 5′-FAM labeledRNA (45 pmol) was
mixed with water to a total volume of 13 l. Next, 6 l an-
nealing buffer (200 mM KCl, 2 mM EDTA, pH 7.5) was
added, and the temperature raised to 90◦C for 2 min. The
sample was then allowed to reach room temperature. RNase
H1 enzyme (LuBioScience, Zu¨rich, Switzerland) was added
(0.125 U in 3.125 l of 750 mM KCl, 500 mM Tris–HCl,
30 mMMgCl2 and 100 mM dithiothreitol, pH 8.3) and the
sample was incubated at 37◦C for 30min before the reaction
was terminated by adding 4 l EDTA solution (0.25 M).
The following buffers were used: buffer A (10 mMNaClO4,
1 mM EDTA, 20 mM Tris–HCl, pH 7.8) and buffer B (1
mM NaClO4, 1 mM EDTA, 20 mM Tris–HCl, pH 7.8).
Following RNase H1 treatment, 15 l of each sample was
mixed with 200 l of buffer A, and 50 l of the result-
ing mixture was subjected to Anion Exchange High Perfor-
mance Liquid Chromatography (AIE-HPLC) on a DNA-
Pac PA100 high-resolution column (2 × 250 mm). Using a
flow rate of 0.25 ml/min, the gradient of buffer A to buffer
B in the column was changed from 100%/0% at time t =
0 min, to 78%/22% at t = 22 min and then to 0%/100%
at t = 25 min. This gradient was then maintained until t =
30 min. Subsequently, the flow rate was then increased to
0.5 ml/min, and the gradient of buffer A to buffer B was
changed to 100%/0% at t = 31 min, and maintained until
t = 35 min. The flow rate was then decreased again to 0.25
ml/min, and the gradient maintained at 100%/0% until t=
40 min. The FAM fluorophore on the RNA was excited at
494 nm, and the emitted light measured at 518 nm. Indi-
vidual peaks in the resulting chromatograms corresponded
to cleaved RNA fragments and remaining full-length RNA.
The amount of each RNA fragment was quantified as the
percentage area under the corresponding peak relative to
the total area under all peaks measured. The percentage of
full-length RNA cleaved represents the RNase H activity
for the gapmer (referred to as % cleaved RNA).
In vivo studies
Inbred C57BL/6J female mice were obtained from Taconic
(Ejby, Denmark) and fed with a standard diet ad libitum.
At the start of the study, the mice weighed 20 ± 2 g (arith-
metic mean± standard deviation). The vivarium was main-
tained on a 12-hour light-dark cycle throughout each study.
Two study schedules were used. For the short studies, mice
were dosed intravenously on days 0, 1 and 2, and anes-
thetized (70% CO2/30% O2) before sacrifice by cervical dis-
location on day 3. For the long studies mice, were dosed
intravenously on days 0, 3, 7, 10 and 14, and sacrificed on
day 16. The treatment groups (n = 5) received either 0.9%
saline or saline-formulated gapmer administered by intra-
venous injection. At the end of the study, blood was sam-
pled for serum analysis, and livers were snap-frozen in liq-
uid nitrogen and stored at−80◦C.All mouse protocols were
approved by the Danish National Committee for Ethics in
Animal Experiments.
Serum alanine-aminotransferase analysis
Serum was analyzed for alanine-aminotransferase (ALT)
activity using an enzymatic assay (Horiba ABX Diagnos-
tics) according to the manufacturer’s instructions adjusted
to 96-well format.Measurements were correlated to a 2-fold
diluted standard curve generated from anABXPentraMul-
tiCal solution (Horiba ABX Diagnostics). The mean ALT
activity in the saline treated group was calculated and all
ALT levels presented as fold changes relative to that mean
value.
RNA analyses from mouse liver: isolation, qRT-PCR and mi-
croarray
Total RNA from liver was isolated using Trizol (Invitrogen,
Denmark), purified using mini RNeasy columns (Qiagen,
Denmark), contaminating DNA removed by treating with
DNase I (Sigma-Aldrich, Denmark) and the integrity and
purity assessed using an Agilent Bioanalyzer (Agilent Tech-
nologies, Santa Clara, USA) and a NanoDrop RNA 6000
spectrophotometer (Thermo Fisher Scientific, Denmark).
Quantification of mRNA by real-time quantitative reverse
transcription polymerase chain reaction (qRT-PCR) was
performed using TaqMan assays (Applied Biosystems, Fos-
ter City, USA) (Supplementary Table S1). The reverse tran-
scription reaction was carried out with random decamers,
0.5 mg total RNA and the M-MLV RT enzyme (Am-
bion, Denmark) according to the protocol for first strand
cDNA synthesis. Depending on expression levels, cDNA
was subsequently diluted (5×) in nuclease-free water be-
fore addition to the RT-PCR reaction mixture. The Ap-
plied Biosystems 7500/7900/ViiA real-time PCR instru-
ment was used for amplification. As a reference, mRNA lev-
els were normalized to -actin (Actb) and glyceraldehyde-
3-phosphate dehydrogenase (Gapdh) and presented as fold-
changes relative to average levels in saline controls. Quan-
tification of mRNA by microarray was conducted using
Affymetrix GeneChip Mouse Gene 1.0 ST Arrays ac-
cording to manufacturer’s specifications (Affymetrix, Santa
Clara, USA). Total RNA was amplified and labeled us-
ing the Whole Transcript Sense Target Labeling Assay
(Affymetrix). Labeled ssDNA was hybridized to arrays in
a GeneChip Hybridization Oven 640 (Affymetrix). The ar-
rays were washed and stained in a GeneChip Fluidics Sta-
tion 450 (Affymetrix), and subsequently scanned with a
GeneChip Scanner 3000 (Affymetrix). The resulting im-
ages were analyzed using Affymetrix Expression Console
Software (Affymetrix). Affymetrix probes were remapped
to 22 361 different gene models using the Ensembl build
77 database (20). Using these redefined probesets, probe in-
tensities were summarized and made comparable between
arrays by quantile normalization using the Robust Multi-
Array Average (RMA) expression measure (21). All data
were submitted to the Gene Expression Omnibus with ID:
GSE100699. Only the 13 959 genes with normalized and
log2-transformed expression levels above 6 in at least one
saline-treated sample were judged to be expressed in liver
and analyzed further.
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Isolation of mouse primary hepatocytes and RNA analysis by
qRT-PCR
A C57BL/6J mouse (Taconic, Ejby, Denmark) was anes-
thetized with pentobarbital and the liver perfused at a
flow rate of 7 ml per min through the vena cava using a
two-step protocol: (i) pre-perfusion for 5 min with Hank’s
balanced salt solution containing 15 mM HEPES and
0.38 mM EGTA and (ii) perfusion for 12 min with col-
lagenase solution (Hank’s balanced salt solution contain-
ing 0.17 mg/ml Collagenase type 2 (Worthington 4176),
0.03% bovine serum albumin, 3.2 mM CaCl2 and 1.6 g/l
NaHCO3). Following removal of the liver and opening of
the liver capsule, the liver suspensionwas filtered through 70
m cell strainer using William E medium (WME) followed
by filtering through 40 m cell strainer. Cells were washed
with WME with 10% fetal bovine serum (WME w/FBS).
The cell suspension was centrifuged for 5 min at 50 g at
room temperature to pellet the hepatocytes. The cell pellet
was re-suspended in 25 ml WME w/FBS, and 25 ml WME
with 90% Percoll solution was added. The cell suspension
was centrifuged for 10 min at 50 g at room temperature, and
the resulting pellet re-suspended in 50 ml WME and again
centrifuged for 3 min at 50 g. At last, the supernatant was
removed and the cells re-suspended in 20 ml WMEw/FCS.
A volume of 100 l of freshly isolated hepatocyte cells were
seededwith 25 000 cells/ml in collagen-coated 96-well plates
and incubated for 3–4 h at 37◦C. After 3–4 h, the cells were
washed with WME w/FBS and 95 l/well WME w/FBS
were added. To this was added a 5 l dilution of oligonu-
cleotide to reach the final concentration range for a 8-point
concentration response curve starting at 50 M with half-
logarithmic dilution (reduced 3.16-fold per point). Cells in-
cubated with oligonucleotide in this manner were harvested
after 3 days by removal ofmedia followed by addition of 125
l PureLinkC©Pro 96 Lysis buffer (Invitrogen 12173.001A)
and 125l 70% ethanol. RNAwas purified according to the
manufacture’s instruction and eluted in a final volume of 50
l water resulting in anRNA concentration of 10–20 ng/l.
RNA was diluted 10-fold in water prior to the one-step
qPCR reaction. For one-step qPCR reaction qPCR-mix
(qScriptTMXLE 1-step RT-qPCR ToughMix®Low ROX
from QauntaBio, cat.no 95134–500) was mixed with two
Taqman probes in a ratio 10:1:1 (qPCRmix: probe 1: probe
2) to generate themastermix. Taqman probes were acquired
from LifeTechnologies (Supplementary Table S1). Master-
mix (6l) andRNA (4l, 1–2 ng/l) weremixed in a qPCR
plate (MicroAmp®optical 384 well, 4309849). After seal-
ing, the plate was given a quick spin, 1000 g for 1 min at
room temperature and transferred to a ViiaTM 7 system
(Applied Biosystems, Thermo), and the following PCR con-
ditions used: 50◦C for 15 min; 95◦C for 3 min; 40 cycles of:
95◦C for 5 s followed by a temperature decrease of 1.6◦C/s
followed by 60◦C for 45 s. The data were analyzed using the
QuantStudioTM Real time PCR Software.
RNA isolation from human cells and analysis by qRT-PCR
The HeLa cell line was purchased from the European Col-
lection of Authenticated Cell Cultures (through Sigma-
Aldrich, Denmark) andmaintained as recommended by the
supplier in a humidified incubator at 37◦C with 5% CO2.
For assays, 2500 HeLa cells/well were seeded in a 96 multi-
well plate in culture media. Cells were incubated for 30
min before addition of oligonucleotides dissolved in PBS
and harvested 3 days later. RNA was extracted using the
PureLink Pro 96 RNA Purification kit according to the
manufacturer’s instructions (Ambion). From this, cDNA
was synthesized using M-MLT Reverse Transcriptase, ran-
dom decamers RETROscript and RNase inhibitor (Am-
bion) with 100 mM dNTP set PCR Grade (Invitrogen) and
DNase/RNase free water (Gibco) according the manufac-
turers’ instructions. For gene expression analysis, qPCRwas
performed using TaqMan Fast Advanced Master Mix (2×)
(Ambion) in a doublex set-up. All primer sets were pur-
chased from Life Technologies (Supplementary Table S1).
The qPCR primer sets for the genes of interest were la-
beled with FAM-MGB dye, while the qPCR primer sets for
the housekeeping PKG1 and PPIA were labeled with VIC-
MGB dye.
Statistical analysis of concentration-response curves
Concentration-response curves (CRCs) of RNA levels af-
ter treatment with gapmer at eight different concentrations
were analyzed by nonlinear least squares fitting of a four-
parameter logistic function using the R software package
drc (22). From each fitted curve the parameter and error es-
timates were tabulated. For each gapmer, selectivity ratios
against each off-target were calculated as the EC50 (half-
maximal effective concentration) value for that off-target
relative to the EC50 value for the on-target. The standard de-
viation of the selectivity ratio was calculated by error propa-
gation of the standard deviations of the individual EC50 es-
timates. Significance of differences between EC50 estimates
are calculated from the corresponding standard errors of
each EC50 using the delta method (22).
Statistical analysis of microarray data
For each transcript, the effects of gapmer treatment were
contrasted with the effects of saline treatment by calculating
log2-transformed expression fold-changes. The significance
of this differential expression was evaluated by empirical
Bayes-moderated F-statistics using the R software package
LIMMA (23). Using the step-up procedure proposed by
Benjamini andHochberg in 1995 (24), transcripts with false
discovery rates (FDRs) below 0.01 were considered signif-
icantly regulated or affected. Conversely, transcripts with
FDRs > 0.1 were considered not significantly regulated or
affected.
Sequence analysis
Hybridization between two complementary nucleic acid
strands is mainly governed by hydrogen bonding between
base pairs on opposite strands and base stacking. In addi-
tion, nucleic acid polymers are flexible and can form bulges
or loops that also need to be considered when evaluating the
thermodynamically optimal hybridization (25–27). Energy
parameters for the binding of LNA-modified phosphoroth-
ioate oligonucleotides to RNA have not been published, al-
though the LNA-modification is known to induce anRNA-
like conformation of theDNA (28). In accord with previous
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(A1) GTtgacactgTC (A2) GCattggtatTCAApob
(P1) GATacacctccACC (P2) GTctgtggaaGCGPcsk9
intron
exon, CDS
exon, UTR
13787 to 13798 33921 to 33933
9693 to 9706 9799 to 9811
Figure 1. Overview of gapmer designs and intended targets. Gene struc-
tures of mouse Pcsk9 with arrows indicating binding regions for gapmers
P1 and P2, and of mouse Apob targeted by gapmers A1 and A2. Positions
are relative to the transcription start site. For each gapmer sequence, up-
percase bold indicates LNA and lower case indicates DNA.
reports of LNA-gapmers (12), we therefore made a rough
estimate of the standard free energy of binding, G, us-
ing parameters for RNA–RNA interactions (27). In addi-
tion, we calculated a simple binding score between oligonu-
cleotide andRNAusing theNeedleman–Wunsch algorithm
(29). The oligonucleotide sequences are listed in Table 1,
and the pre-mRNA and mRNA sequences were retrieved
from the Ensembl build 77 database (20). The Needleman–
Wunsch alignment was performed without end gap and
gap opening penalties, with a gap extension penalty of −1
and with substitution scores of 1 for each Watson–Crick
base pair and zero otherwise. The maximal score using this
scheme is equal to the length of the oligonucleotide.
RESULTS
Reproducible reduction of target mRNA in mouse liver after
gapmer treatment
We designed and synthesized two different pairs of LNA
phosphorothioate antisense oligonucleotides (gapmers).
One pair, P1 and P2, targeted mouse Pcsk9 in non-
overlapping but fairly close target regions, while the other
pair, A1 and A2, targeted mouseApob in widely distant tar-
get regions (Figure 1 andTable 1). Gapmers P2 (30), A1 (31)
andA2 (32) have previously been investigated. To reduce the
potential for mismatched binding of either P1 or P2 toApob
or for A1 or A2 to Pcsk9, the target regions of P1 and P2
in Pcsk9 were chosen so that there were at least three mis-
matches or bulges to any target region in Apob. Similarly
A1 and A2 were designed with at least three mismatches or
bulges to any target region in Pcsk9.
C57BL/6Jmice (n= 5 per group) were administered each
of the four different gapmers by three intravenous injec-
tions on consecutive days. Knockdown of Pcsk9 and Apob
mRNA in the liver at day 4 was measured by qRT-PCR
(Figure 2). As seen in Figure 2A, the gapmers P1 and P2 sig-
nificantly reduced Pcsk9 target mRNA levels to ∼50% and
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Figure 2. Confirmation of gapmer activity on intended targets. Knock-
down of (A) Pcsk9 mRNA and (B) Apob mRNA in mouse liver as mea-
sured by qRT-PCR following three 10 mg/kg doses on consecutive days
of gapmers P1 and P2 (targeted to Pcsk9), or 10 and 5 mg/kg, respec-
tively, of A1 and A2 (targeted to Apob). Data represent the average ± one
standard deviation relative to saline-treated controls (Ctrl) with n = 5 per
treatment group. Significance of differences in average transcript levels be-
tween groups evaluated by Student’s t-test. *P< 0.05, **P< 0.01, ***P<
0.001, ns: not significant.
∼30%, respectively, compared to those in saline control-
treated mice. In Figure 2B, the gapmers A1 and A2 sig-
nificantly reduced Apob target mRNA levels to <5% and
∼10%, respectively. To match activity on the intended tar-
get, based on the potency measured in primary mouse hep-
atocyes (data not shown), P1 and P2 were both dosed at
10 mg/kg, whereas A1 and A2 were dosed at 10 and 5
mg/kg, respectively. The Pcsk9 targeting gapmers, P1 and
P2, did not affect Apob mRNA levels (Figure 2B), while
conversely, the Apob targeting gapmers, A1 and A2, both
reduced Pcsk9 mRNA levels to ∼60% (Figure 2A). This
observation suggested that the reduction of Pcsk9 mRNA
levels is a downstream effect of Apob mRNA knockdown,
which is consistent with a previous study assessing the im-
pact of human PCSK9 overexpression in mice (19).
These results were reproduced in an independent mouse
experiment (Supplementary Figure S1). In summary, the
gapmers P1, P2, A1 and A2 mediated significant knock-
down of their intended targets in liver as expected.
Identification of effects from intended- and unintended tar-
gets in mice liver
To further characterize the effects of the four gapmers, P1,
P2,A1 andA2, on the transcriptomes inmouse liver, we per-
formed a microarray analysis of the RNA from the study
presented in Figure 2. For each of the four gapmers, we
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Table 1. Sequence and LNA-modification patterns for gapmers in study
Name Target Sequence (5′ to 3′)a Length (nt) Tm (◦C)
P1 Pcsk9 GATacacctccACC 14 69.0
P2 Pcsk9 GTctgtggaaGCG 13 63.8
A1 Abob GTtgacactgTC 12 54.1b
A2 Apob GCattggtatTCA 13 59.5
U1 UBE3C GTgtttctgcTGCT 14 73.0
U2 UBE3C GTGTttctgctgcTAT 16 72.1
U3 UBE3C GTGTttctgctgctATAA 18 72.2
U4 UBE3C TGgtgtttctgctgctATAA 20 68.4
T1 Tradd GctcatactcgtaggcCA 18 66.8
T2 Tradd GCtcatactcgtaggcCA 18 69.7
T3 Tradd GCtcatactcgtaggCCA 18 72.1
T4 Tradd GCTcatactcgtaggcCA 18 73.3
T5 Tradd GCTcatactcgtaggCCA 18 76.3
aUpper case plus bold font indicates LNA and lower case indicates DNA. All nucleotides are phosphorothioate-linked.
bMelting curves did not have normal sigmoidal shape so Tm estimate may be biased.
found that levels of hundreds of transcripts were signifi-
cantly lower or higher after treatment compared to those
in the saline-treated control, when controlling for the FDR
at 0.01 (Figure 3A and B).
At the significance cutoff-levels chosen, as for the qRT-
PCR analysis (Figure 2), ApobmRNA was identified in the
microarray analysis as significantly reduced by both A1 and
A2, but not by P1 and P2. Furthermore, Pcsk9mRNA was
reduced by all four gapmers, although the P1 and P2 gap-
mers had the greatest effect (Supplementary Tables S2–5).
Besides Pcsk9, the microarray analysis revealed 39 tran-
scripts that were significantly reduced by both P1 and P2
(Figure 3C), which is a larger overlap than expected by
chance (P< 10−16 by Fisher’s Exact test). Presumably, these
transcripts are involved in downstream processes that are
affected by reductions in Pcsk9 RNA levels. Moreover, 58
transcripts were identified that were significantly reduced by
treatment with P1, but were not significantly affected (FDR
> 0.1) by P2. In addition, 150 transcripts were significantly
reduced by P2, but not by P1 (Figure 3C). This analysis
was repeated for the Apob targeting gapmers, A1 and A2,
to identify groups of transcripts that were significantly re-
duced by treatment with both gapmers (104 genes), or with
only one of the gapmers (128 for A1 and 222 for A2) (Figure
3D). Furthermore, among the 104 transcripts significantly
reduced by both A1 and A2, which again was a higher num-
ber than expected by chance (P < 10−16 by Fisher’s Exact
test), 11 were found to also be significantly reduced by P1
and P2. This set of transcripts could be involved in Pcsk9-
mediated downstream effects of Apob mRNA knockdown
(Supplementary Table S6). Alternatively, the 11 transcripts
could be reduced simply due to a general effect of treatment
with any oligonucleotide. Re-analysis of previously pub-
lished liver transcriptome data after treatment with a LNA-
modified oligonucleotide (33) did not reveal such a gen-
eral reduction relative to saline-treated controls for this set
of genes (Supplementary Table S6), however these oligonu-
cleotides were designed to sequester microRNAs, not acti-
vate RNase H. Further transcriptome studies with proper
negative control oligonucleotides will be needed to confirm
if these transcripts are indeed involved in Pcsk9-mediated
downstream effects of Apob mRNA knockdown. With re-
spect to identification of off-targets of A1, A2, P1 and P2,
which is the focus in this study, the effects of gapmer A2-
treatment on the transcriptome were largely reproduced in
an independentmouse study, confirming the reproducibility
of the microarray analysis and the identification of affected
transcripts (Supplementary Figure S2).
Sequence analysis identifies partially complementary off-
target sites
For each gapmer, we hypothesized that there was an enrich-
ment of direct, RNase H-mediated, off-targets among the
groups of transcripts identified in the microarray analysis
as being reduced exclusively by that gapmer (Figure 3C and
D). Such off-targets have, by definition, one or more tar-
get sites where the gapmer can bind and elicit cleavage via
the RNase H-mechanism. We therefore analyzed all 13 959
RNA sequences identified as being expressed in mouse liver
in the microarray analysis for potential binding sites. For
each gapmer and RNA sequence, we identified the region
in the RNA sequence with the computationally calculated
lowest possible free energy of binding (G) to the gapmer.
For comparison of these calculated binding affinities for all
possible unintended RNA targets (Goff) with the calcu-
lated binding affinity to the intended RNA target (Gon),
we calculated G values as the difference between Goff
and Gon. That is, more positive G values indicate
weaker binding between the gapmer and unintended RNA,
relative to the strength of the binding between the gapmer
and the intended target RNA. In Figure 4A–D, for each
of the four groups of transcripts identified as exclusively
affected by each gapmer, P1, P2, A1 and A2, the corre-
spondingGvalues (colored boxes/lines) were compared
to the G values for the rest of the transcripts included
in the microarray analysis (gray boxes/lines), as boxplots
and cumulative fractions. For the transcripts in each of the
four groups, those harboring strong binding regions to that
gapmer in their RNA sequence (roughly G-values < 5
kcal/mol) were significantly over-represented compared to
all other transcripts (Figure 4A–D).
As an alternative approach to the identification of po-
tential gapmer binding sites, which does not rely on esti-
mating G, we also counted the number of Watson–Crick
base pairs between the gapmer and the RNA sequence in
5372 Nucleic Acids Research, 2018, Vol. 46, No. 11
147
10074
167
1020
7846
326
150 58
39
A
C
438
9358
355
409
9106
492
222 128
104
B
D
P1 vs Ctrl P2 vs Ctrl
Pcsk9
A1 vs Ctrl A2 vs Ctrl
Apob
P2 only P1 only A2 only A1 only
P1 and P2 A1 and A2
Figure 3. Overview of gapmer treatment effects on the transcriptome (A) Transcripts are divided into those significantly increased (up arrow), decreased
(down arrow), or not affected (dot) after treatment with P1 (blue) or P2 (green). Similarly, for (B) significantly increased (up arrow), lowered (down arrow)
or not affected (dot) transcript levels after treatment with A1 (orange) or A2 (purple) are shown. (C) The three overlapping sets of transcripts that are
focused on in this analysis are outlined: those reduced by treatment with P1 but not affected by treatment with P2 (P1 only), those reduced by treatment with
P2 but not affected by treatment with P1 (P2 only) and those significantly reduced by both P1 and P2. Similarly for (D) the overlapping sets of transcripts
reduced by either A1 only, A2 only or by both A1 and A2.
0.0
0.2
0.4
0.6
0.8
1.0
C
um
ul
at
iv
e 
fra
ct
io
n
0 5 10 15
0.0
0.2
0.4
0.6
0.8
1.0
∆∆G˚ (difference in minumum free energy change)
C
um
ul
at
iv
e 
fra
ct
io
n
0 5 10 15
P1 only (n=58)
Rest (n=13901)
P2 only (n=150)
Rest (n=13809)
A1 only (n=128)
Rest (n=13831)
A2 only (n=222)
Rest (n=13737)
P < 5×10-5
D = 0.30
P < 10-15
D = 0.57
P < 10-15
D = 0.63
P < 10-15
D = 0.33
A
C
B
D
P < 5×10-4 P < 10-15
P < 10-15P < 10-15
Figure 4. Characterization of partially complementary off-target binding sites by calculation of free energy of binding. For each of the gapmers (A) P1,
(B) P2, (C) A1 and (D) A2, transcripts were grouped into those specifically reduced by that gapmer (Figure 3C and D) and the rest, and the distribution of
differences in free energy changes displayed as boxplots and cumulative fractions. Significance of differences between groups of transcripts were evaluated
byWilcoxon Rank Sum test for boxplots, and the Kolmogorov–Smirnov test for cumulative fractions. The test statisticD is the maximum vertical deviation
between two cumulative fraction curves.
Nucleic Acids Research, 2018, Vol. 46, No. 11 5373
the region that allows optimal alignment. According to this
method, a gapmer binding to a fully matched RNA target
will have a binding score equal to the length of the gapmer,
while a gapmer binding with onemismatch will have a bind-
ing score equal to its lengthminus 1, and so forth. As shown
in Figure 5A–D, the results obtained using this method
were consistent with those obtained when quantifying bind-
ing sites by estimating G (Figure 4A–D), for each gap-
mer, P1, P2, A1 and A2. RNA sequences with high binding
scores (≤2 mismatches or bulges) were significantly over-
represented among the groups of transcripts exclusively af-
fected by each gapmer, compared to all other transcripts.
These results provide evidence for the over-representation
of binding sites with characteristics as expected for direct,
RNase H-mediated, off-targets among the transcripts sig-
nificantly reduced by each of the gapmers, as identified ei-
ther by thermodynamic evaluation of the change in free en-
ergy of binding (Figure 4A–D), or by the binding score of
the number of Watson–Crick base pairs (Figure 5A–D).
Properties of potential off-targets as substrates for RNase H
To evaluate the capacity of potential off-target binding sites
identified by sequence analysis as substrates for RNase H
when duplexed with a gapmer, we selected 23 of the 222
transcripts reduced exclusively by A2 (Figure 3D). The cri-
teria for the selection were: (i) transcript levels reduced by
at least 2-fold following treatment with A2, and (ii) a bind-
ing score of at least 9; that is, no more than four mis-
matches or bulges. Of these 23 potential off-target binding
sites, four were identical. Therefore, only 20 unique RNA
oligonucleotides were synthesized (Supplementary Table
S7). For each of the synthesized RNAs, we measured Tms
and RNase H-cleavage activity toward A2 (Supplementary
Table S7). The results are summarized in Figure 6A.
We identified three groups of RNA sequences. A group
of 11 RNAs, represented by green dots in Figure 6A, had
reasonably similar binding affinities to the fully matched
Apob binding site for A2, represented by the black dot (Tm
> 50◦C), as well as RNase H-cleavage activity similar to or
better than the that associated with the Apob binding site
(more than 40% cleaved). Therefore, these data indicate that
the 11 transcripts harboring these RNA target sites are A2
off-targets. A group of five RNA sequences, represented by
orange dots in Figure 6A, had low binding affinity to A2
(Tm < 50◦C) and only modest or no RNase H-cleavage ac-
tivity when duplexed to A2 (<30% cleaved RNA). Based
on these data, it is therefore not likely that these sites are
functional. Alternatively, the reduced expression of these
transcripts could be explained as secondary effects of en-
gaging one or more of the off-targets of A2 identified in
the green group (Figure 6A). For the group of four RNA
sequences represented by blue dots, it was not possible to
judge whether they are off-targets or not. On the one hand,
the binding affinity was very low (Tm < 45◦C), making it
less likely that enough duplex can form in vivo to catalyze
substantial degradation. On the other hand, the RNase H-
cleavage activity is similar to, or better than, that for the
Apob site (black dot), indicating that the cleavage reaction
can be effective if enough duplex is formed in vivo. Strat-
ification of the sequence analysis results for the set of 23
transcripts (Supplementary Table S7) into the three groups
discussed above, revealed that the 11 transcripts with char-
acteristic most similar to Apob binding site (green dots in
Figure 6A), had significantly lowerGvalues (Figure 6B)
and significantly higher binding scores (Figure 6C) than the
rest in the selected set.We repeated the cleavage experiments
with twice the concentration of RNase H enzyme and ob-
served the same ranking of gapmers (data not shown).
Reducing off-target effects by lowering the binding affinity
toward on- and off-targets
The binding affinity between gapmers and fully matched as
well as mismatched target sites can be modulated by chang-
ing the number of LNA modifications in the gapmers. To
investigate howmodulating the binding affinity in this man-
ner can affect knockdown activity of transcripts harboring
fully matched or mismatched target sites, we designed five
gapmers, T1–T5, targeting the same 18 nt site in the mouse
tumor necrosis factor receptor type 1-associated DEATH
domain protein (Tradd) transcript (Figure 7A). The gap-
mers were modified with three to six LNAs, with T1 having
the lowest Tm value at 66.8◦C and T5 having the highest at
76.3◦C (Table 1 and Figure 7A). Gapmers designed as T2
and T5 have been evaluated previously in mice (34). Using
sequence analysis, we identified 34 mouse transcripts with
no more than two mismatches or bulges (binding score ≥
16) to T1–T5. Of these, 11 were judged to be expressed in
mouse liver based on the microarray data generated for the
studies presented in Figures 2 and 3. Of these 11 transcripts,
the two with the lowestGvalues to their predicted bind-
ing sites, protein tyrosine phosphatase, receptor type D (Pt-
prd) and adiponectin receptor 1 (Adipor1), were selected as
the most likely potential off-targets. We administered each
of the five different gapmers by five intravenous injections
of 15 mg/kg in C57BL/6J mice (n= 5 per group) over a 14-
day period. The knockdown of Tradd, Ptprd and Adipor1
mRNA was measured in the liver at day 16 by qRT-PCR
(Figure 7B).
For Tradd, all five gapmers significantly reduced mRNA
levels to between 10 and 15%, with no significant statisti-
cal differences between the degrees of knockdown. In con-
trast, the greatest knockdown of Ptprd was observed with
T3, which significantly reduced transcript levels to ∼40%.
For Adipor1, only T3 significantly reduced transcript levels
to ∼70% compared to the effects of the saline control.
For this dosing schedule in mice, the gapmer T1 signif-
icantly reduced Tradd mRNA levels without significantly
affecting Ptprd or Adipor1. Increasing the binding affinity
further with T2 to T5 did not significantly improve Tradd
knockdown, whereas T2, T3 and T5 did mediate significant
knockdown of Ptprd, as did T3 for Adipor1. Therefore, T1
was identified as the most sequence-specific gapmer in the
set of T1–T5, achieving the best balance between knock-
down of intended- and unintended targets.
The dosing schedule used in the mouse study is a stan-
dard schedule used for evaluating the hepatotoxic potential
of LNA-modified gapmers (35). Measurements of ALT, a
biomarker of hepatocellular injury, in serum at day 16 re-
vealed that T2, T3 and T5 had significantly higher hepato-
toxic potential compared to T1 (Figure 7C). In particular
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T3, which was found to be the least sequence-specific when
comparingTradd toPtprd andAdipor1 (Figure 7B), had the
highest hepatotoxic potential in the set of T1–T5, with ALT
levels 60-fold above saline treated control.
To further evaluate efficacy and potency of the gapmers
T1–T5, knockdown of Tradd was also evaluated by qRT-
PCR inmouse primary hepatocytes (n= 4) at eight different
concentrations between 0.016 and 50 M. From the result-
ing CRCs, see Figure 7D, both maximal efficacy as well as
EC50 values were estimated (Supplementary Table S9, hori-
zontal and vertical dashed lines in Figure 7D). Themaximal
efficacies for T1–T5 were all around 15%mRNA relative to
PBS control and not significantly different from each other.
This efficacy is comparable to the knockdown observed in
the mice studies, and suggests that the total administered
dose of 75 mg/kg of each gapmer in mice resulted in very
high intracellular concentrations of gapmers in liver, and in
the maximally achievable knockdowns of the intended tar-
get (compare Figure 7B and D). The EC50 values for gap-
mers T1-T5 were between 1 and 3 M, and also not signif-
icantly different from each other. For comparison, the two
off-targets Ptprd and Adipor1 were also evaluated in mouse
primary hepatocytes, but unfortunately even at the highest
concentration of 50 M, none of the gapmers T1–T5 re-
duced RNA levels significantly (data not shown). The fact
that Ptprd and Adipor1 were reduced by some of the gap-
mers in the studies in mice supports the observation made
above that the dosing schedule used in the mice studies re-
sulted in very high intracellular concentrations of gapmers
in the livers of mice.
Taken together, at very high dose levels in mice, the gap-
mer T1 was identified as the most sequence-specific gapmer
in the set of T1–T5 (Figure 7B), and as the gapmer with the
lowest hepatotoxic potential (Figure 7C). In primary hepa-
tocytes, the gapmers T1–T5 were identified as having fairly
similar efficacy and potency on the intended target Tradd,
andwith tooweak potency on the off-targetsPtprd andAdi-
por1, to have measureable knockdown within the concen-
tration range used.
Reducing off-target effects by lowering the binding affinity
toward off-targets only
By increasing the length of a gapmer, the extended part
may cover regions that are not fully matched to the un-
intended targets. The more mismatches or bulges between
a gapmer and a RNA binding region, the lower the bind-
ing affinity relative to a fully matched RNA binding region,
and presumably, the weaker the potency (11). To investigate
the mechanism by which introduction of such differences in
binding affinity between intended and unintended targets
can affect off-target effects, we designed and synthesized
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four different gapmers, U1–U4. These gapmers targeted the
same core region in the human ubiquitin protein ligase E3C
(UBE3C) transcript, but ranged from 14–20 nucleotides in
length (Table 1 and Figure 8A). TheTm values for each gap-
mer binding to the target region inUBE3Cwere in the range
72–73◦C, except for U4, which was slightly lower at 68.4◦C.
WemeasuredUBE3C knockdown by qRT-PCRat eight dif-
ferent concentrations in two different batches of HeLa cells,
and estimated the concentration required to achieve half-
maximal knockdown, EC50, from the resulting CRCs (Sup-
plementary Table S8 and Figure S3).
Based on sequence analysis, we identified 55 human tran-
scripts with one mismatch or bulge (binding score 15) to the
16 nt gapmer,U2.Of these, we selected four that could be re-
liably measured by qRT-PCR in HeLa cells. Using the same
approach as that used forUBE3C,wemeasured knockdown
of each of the four potential unintended target transcripts
and estimated EC50 values from the resulting CRCs (Sup-
plementary Table S8 and Figure S3). We aligned the ex-
pected target regions in each transcript to the target region
in UBE3C (Figure 8A). As shown in Figure 8A, for nudix
hydrolase 19 (NUDT19), two potential target regions were
identified, denoted A and B, respectively. A region identical
to the NUDT19 (A) region was identified in rho guanine
nucleotide exchange factor 7 (ARHGEF7) (Figure 8A).
Next, we synthesized the five RNA sequences (listed in
Figure 8A), and measured the Tm to each of the gap-
mers, U1–U4 (Figure 8B). Comparison of Figure 8A and
B showed that longer gapmers contained more mismatches
(indicated in red), and had lower Tm toward the unintended
target sites relative to the values for the intended target site
in UBE3C.
At last, for each gapmer U1–U4, we calculated the selec-
tivity ratio between the intended target onUBE3C and each
of the four unintended targets as the ratio of estimated EC50
values (Figure 8C). Longer gapmers were associated with a
larger selectivity ratio toward the unintended targets. This
relationship corresponds to weaker potency of activity on
unintended targets relative to that on the intended target,
UBE3C.
DISCUSSION
It is a goal of drug discovery to ensure that the chem-
ical compounds developed interact specifically with their
intended biomolecular targets (36). For oligonucleotide
therapeutics, improvements in potency arising from high-
affinity chemical modifications and improved modes of cel-
lular delivery are recognized in the field as factors that can
potentially increase the risk of off-target-dependent toxic-
ities (11,37). Although this type of adverse event has not
been observed in clinical trials involving oligonucleotide
therapeutics to date, recent studies in mice suggest that the
number of off-targets that are effectively reduced in the liver
after systemic administration of gapmers can be correlated
with the hepatotoxic potential of the oligonucleotides, as
measured using biochemical markers in the blood (13–16).
This underlines the importance of understanding how to
identify and avoid off-targets of gapmers.
To be able to conclude that phenotypic changes observed
after administration of a gapmer are causally related to
cleavage and degradation of the target RNA, it is neces-
sary to test at least two gapmers complementary to the
same RNA target, but with different nucleobase sequences.
If treatment with both gapmers results in the same pheno-
type, whereas treatment with a control gapmer that is not
complementary to the RNA target does not, it strongly sug-
gests that the phenotype is mediated by target degradation
(38).
In this study, we applied the same reasoning to the iden-
tification of off-target effects, and show for two different
RNA targets, Apob and Pcsk9 in mice (Figures 1 and 2),
that changes in the transcriptome resulting from engaging
the intended target can be separated from those related to
engaging unintended off-targets (Figure 3).
Both pairs of gapmers reduced the intended target to
slightly different extents (Figure 2), and the separation of
intended and unintended effects can therefore not be ex-
pected to be complete. Also, some transcripts might be re-
duced as downstream effects of a reduction in actual off-
targets. As a result, not all transcripts in the sets of potential
off-targets identified by the transcriptome analysis (Figure
3C and D) are expected to be off-targets themselves. Nev-
ertheless, analysis of the binding site characteristics of the
sets of potential off-targets revealed that binding sites with
no- or only few mismatches or bulges to the gapmer, and
consequently having a binding affinity close to that of the
intended RNA target, were enriched in these sets (Figures 4
and 5).
For the transcripts that are not reduced by treatment
and therefore not likely to be direct, RNase H-mediated,
off-targets (gray lines and gray bars in Figures 4 and 5),
some of them harbor sequence regions with no- or only few
mismatches or bulges to the gapmer. This suggests that se-
quence regions with characteristics that allow gapmer bind-
ing are a necessary factor, but not the only factor, that in-
fluences gapmer activity. For example, kineticmodeling pre-
dicts that transcripts with high turnover rates are less likely
to be reduced effectively with gapmers (39), and experi-
ments in cells and in cell-free environments show that off-
target regions are more likely to be found in unstructured
and accessible parts of the RNA (40). This underscores the
importance of combining sequence-analysis with transcrip-
tomics to allow exclusion of false positives harboring bind-
ing sites that in principle allow gapmer binding, but where
other factors negate possible gapmer activity, and as a con-
sequence no appreciable reduction of RNA is seen.
Two hallmarks of binding sites in off-targets are: (i) suffi-
cient binding affinity to the gapmer to form stable duplexes,
and, (ii) sufficient RNase H-cleavage of the RNA in these
duplexes to reduce overall RNA levels effectively. For a se-
lected set of 23 potential off-target transcripts clearly re-
duced by treatment with gapmer A2, we therefore measured
Tms and RNase H-cleavage activities for the most likely
binding regions in each. We found that around half of these
transcripts had Tms and cleavage activities similar to those
measured for the duplex between the gapmer and intended
target RNA (green dots in Figure 6). Sequence analysis re-
vealed that this half had the fewest mismatches or bulges to
their putative off-targets. Using the transcriptomics proto-
col presented here, combined with follow-up experimental
validation of duplex stability and cleavage, off-target candi-
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binding toUBE3C and each of the unintended targets. (C) For each of the unintended targets, the EC50 for each gapmer relative to the EC50 forUBE3Cwas
estimated from an 8-point CRC measured by qRT-PCR (n = 2). Error bars represent one standard deviation as determined from the nonlinear regression
using error propagation.
dates can be identified with high probability. If needed, off-
target potential could be further supported by character-
izing cleavage products, using for example, 5′-RACE (41),
and confirming that cleavage occurred at the predicted gap-
mer binding site. Interestingly, some of the off-targets of the
gapmer A2 identified in this manner were found to be better
substrates for RNase H than the intended target sequence
inApob, and were also reduced more effectively than the in-
tended target (see Supplementary Table S7). This suggests
that RNase H substrate preferences can in some cases con-
tribute even more to the activity on off-targets than on the
intended target. For other factors, such as RNA accessibil-
ity, a similar situation may exist. In some cases a structured
region may negate potential binding and reduction, as dis-
cussed above, but in other cases, if the potential off-target
region is even more unstructured and accessible than the
region in the intended target, the off-target might be even
more effectively reduced than the intended target because
of this.
Given the ability to screen for likely off-targets then raises
the question of how to best use this to avoid them. A simple
trial and error strategy could be followed, where many gap-
mers are evaluated until one is found that is both sufficiently
potent and specific. Instead of just discarding potent but
unspecific gapmers, however, we suggest two approaches for
optimizing the designs of such gapmers to generate versions
that aremore specific for the intended target. First, the over-
all binding affinity to the RNA could be reduced, for exam-
ple, by decreasing the number of LNA modifications in the
gapmer. We demonstrated this approach for five gapmers
targeted to the same region in the Tradd transcript, and
evaluated Tradd knockdown in mouse liver and primary
mouse hepatocytes relative to the knockdown of two off-
targets (Figure 7). The gapmer T1 with the lowest binding
affinity of the five gapmers evaluated was identified as most
sequence-specific and also the one with the lowest hepato-
toxic potential. Second, the difference in binding affinities
between intended and unintendedRNA could be increased.
This can be achieved by increasing the length of the gapmer
in the cases where the off-target regions then become mis-
matched to the gapmer. For this approach to succeed, the
binding affinity to the intended target region must remain
as constant as possible, for example by reducing the number
of LNAmodifications as the length of the gapmer increases.
We demonstrated this concept for four gapmers of different
lengths targeted to the same core region in theUBE3C tran-
script, and evaluated UBE3C knockdown in human HeLa
cells relative to the knockdown of four off-targets (Figure
8).
Recent studies relating gapmer binding affinity to po-
tency (11,39,42) can be used to model and illustrate why
sequence-specificity can be increased by the two approaches
suggested here (Figure 9). The potency of a gapmer is re-
lated to the strength of the binding affinity between gap-
mer and RNA target (11). For gapmers with very low bind-
ing affinity, the propensity to duplex with RNA is low, and
high concentrations of gapmer are needed to form enough
duplex for effective RNase H-cleavage; therefore, the po-
tency of these gapmers will be low. For gapmers with very
high binding affinity, the gapmers will still bind strongly to
the RNA also after cleavage, which stalls the catalytic cy-
cle (39,42); this also weakens the potency of the gapmer.
Consequently, there exists a region of optimal binding affin-
ity, where the potency is highest (39). This parabolic, or U-
shaped, relationship between binding affinity and potency
exists for both intended and unintended targets (black and
gray points in Figure 9, respectively). In this model, the
first approach to reducing off-target effects can be seen as
shifting both points to the right (Figure 9A), so that the
intended target moves from having a higher-than-needed
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Figure 9. Affinity-potency relations suggesting how sequence-specificity can be optimized. Either (A) decrease binding affinity by reducing the number of
high-affinity modifications, or (B) increase gapmer length and thereby, the number of mismatches to off-targets. For both suggestions, the extent of the
optimization must be balanced against maintaining activity on the intended target.
binding affinity, to having the optimal binding affinity for
potency. In contrast, the reduced binding affinity to the off-
target results in weaker potency, as also demonstrated ex-
perimentally (Figure 7). In the second approach, only the
gray off-target point is shifted to the right (Figure 9B), re-
ducing binding affinity to off-targets only.We demonstrated
that this can be achieved by increasing the length of the
gapmer and thereby, introducing mismatched base pairing
to the off-targets (Figure 8). To maintain the same bind-
ing affinity to the intended target, the increased length of
the gapmer is usually balanced by decreasing the number
of LNA modifications. In our experience there is a limit
to how long a gapmer can be without having weaker po-
tency on the intended target compared to a shorter gapmer
with similar affinity binding in the same target region. Such
an effect can for example be explained by the gapmer be-
ing longer than the accessible region on the target, or by
an increased propensity of the long gapmer to form self-
structures. As a consequence, the gapmer length achieving
optimal sequence-specificity varies between different target
regions. A good starting point in most cases is probably a
17–18 nt long gapmer with a predicted Tm between 50◦C
and 55◦C. We would rarely expect that gapmers more than
20 nt in length would be active enough to be taken into con-
sideration.
A major strength of the antisense oligonucleotide tech-
nology is that it enables using sequence information and
transcriptomics to predict potential hybridization-based
off-target effects (11,37). The results presented here demon-
strate how this can be achieved in practice, and suggest two
approaches for optimizing potent gapmers for improved
sequence-specificity. For RNA therapeutics, such optimiza-
tion is an essential aspect of turning interesting leads into
actual drugs, by allowing high potency to be combined with
low toxicity for high-affinity RNase H-dependent antisense
oligonucleotide drugs.
DATA AVAILABILITY
All microarray data were submitted to the Gene Expression
Omnibus with ID: GSE100699
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
Nucleic Acids Research, 2018, Vol. 46, No. 11 5379
ACKNOWLEDGEMENTS
For their excellent technical assistance, we would like to
thank Rikke Sølberg, Henriette L. Press, Heidii Mazur,
Camilla T. Haugaard and Lisbeth Bang for handling of
mice in animal facilities; Marianne B. Mogensen, Kirsten
N. Petersen and Valesi Mukuka for synthesis and formula-
tion of LNA-modified oligonucleotides; Charlotte Øverup
for liver RNA and Tm measurements; and Bettina Nordbo
for RNAmeasurements in primarymouse hepatocytes. Ad-
ditionally, we are grateful to Art Levin and Andreas Petri
for valuable discussions and to Bo R. Hansen for support
in the preparation of the manuscript.
FUNDING
Danish Strategic Research Council [DSF-10-092320].
Funding for open access charge: Roche Innovation Center
Copenhagen A/S.
Conflict of interest statement.All authors except M.P. are
employees of Roche Pharma Research and Early Develop-
ment, a part of F. Hoffmann-La Roche Ltd., a company
that is developing LNA-modified oligonucleotides for ther-
apeutic purposes.
REFERENCES
1. Stein,H. and Hausen,P. (1969) Enzyme from calf thymus degrading
the RNA moiety of DNA-RNA Hybrids: Effect on DNA-Dependent
RNA polymerase. Science, 166, 393–395.
2. Lima,W.F., De Hoyos,C.L., Liang,X.-H. and Crooke,S.T. (2016)
RNA cleavage products generated by antisense oligonucleotides and
siRNAs are processed by the RNA surveillance machinery. Nucleic
Acids Res., 44, 3351–3363.
3. Zamecnik,P.C. and Stephenson,M.L. (1978) Inhibition of Rous
sarcoma virus replication and cell transformation by a specific
oligodeoxynucleotide. PNAS, 75, 280–284.
4. Raal,F.J., Santos,R.D., Blom,D.J., Marais,A.D., Charng,M.-J.,
Cromwell,W.C., Lachmann,R.H., Gaudet,D., Tan,J.L.,
Chasan-Taber,S. et al. (2010) Mipomersen, an apolipoprotein B
synthesis inhibitor, for lowering of LDL cholesterol concentrations in
patients with homozygous familial hypercholesterolaemia: a
randomised, double-blind, placebo-controlled trial. Lancet., 375,
998–1006.
5. Bennett,C.F. and Swayze,E.E. (2010) RNA targeting therapeutics:
molecular mechanisms of antisense oligonucleotides as a therapeutic
platform. Annu. Rev. Pharmacol. Toxicol., 50, 259–293.
6. Woolf,T.M., Melton,D.A. and Jennings,C.G. (1992) Specificity of
antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. U.S.A., 89,
7305–7309.
7. Lennox,K.A., Sabel,J.L., Johnson,M.J., Moreira,B.G., Fletcher,C.A.,
Rose,S.D., Behlke,M.A., Laikhter,A.L., Walder,J.A. and Dagle,J.M.
(2006) Characterization of modified antisense oligonucleotides in
Xenopus laevis embryos. Oligonucleotides, 16, 26–42.
8. Koshkin,A.A., Singh,S.K., Nielsen,P., Rajwanshi,V.K., Kumar,R.,
Meldgaard,M., Olsen,C.E. and Wengel,J. (1998) LNA (Locked
Nucleic Acids): Synthesis of the adenine, cytosine, guanine,
5-methylcytosine, thymine and uracil bicyclonucleoside monomers,
oligomerisation, and unprecedented nucleic acid recognition.
Tetrahedron, 54, 3607–3630.
9. Seth,P.P., Siwkowski,A., Allerson,C.R., Vasquez,G., Lee,S.,
Prakash,T.P., Wancewicz,E.V., Witchell,D. and Swayze,E.E. (2009)
Short antisense oligonucleotides with novel 2′–4′ conformationaly
restricted nucleoside analogues show improved potency without
increased toxicity in animals. J. Med. Chem., 52, 10–13.
10. Kamola,P.J., Kitson,J.D.A., Turner,G., Maratou,K., Eriksson,S.,
Panjwani,A., Warnock,L.C., Douillard Guilloux,G.A., Moores,K.,
Koppe,E.L. et al. (2015) In silico and in vitro evaluation of exonic
and intronic off-target effects form a critical element of therapeutic
ASO gapmer optimization. Nucleic Acids Res., 43, 8638–8650.
11. Hagedorn,P.H., Hansen,B.R., Koch,T. and Lindow,M. (2017)
Managing the sequence-specificity of antisense oligonucleotides in
drug discovery. Nucleic Acids Res., 45, 2262–2282.
12. Rukov,J.L., Hagedorn,P.H., Høy,I.B., Feng,Y., Lindow,M. and
Vinther,J. (2015) Dissecting the target specificity of RNase H
recruiting oligonucleotides using massively parallel reporter analysis
of short RNA motifs. Nucleic Acids Res., 43, 8476–8487.
13. Kakiuchi-Kiyota,S., Koza-Taylor,P.H., Mantena,S.R., Nelms,L.F.,
Enayetallah,A.E., Hollingshead,B.D., Burdick,A.D., Reed,L.A.,
Warneke,J.A., Whiteley,L.O. et al. (2014) Comparison of hepatic
transcription profiles of locked ribonucleic acid antisense
oligonucleotides: evidence of distinct pathways contributing to
non-target mediated toxicity in mice. Toxicol. Sci., 138, 234–248.
14. Burel,S.A., Hart,C.E., Cauntay,P., Hsiao,J., Machemer,T., Katz,M.,
Watt,A., Bui,H.-H., Younis,H., Sabripour,M. et al. (2015)
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is
mediated by RNase H1 dependent promiscuous reduction of very
long pre-mRNA transcripts. Nucleic Acids Res., 44, 2093–2109.
15. Kasuya,T., Hori,S.-I., Watanabe,A., Nakajima,M., Gahara,Y.,
Rokushima,M., Yanagimoto,T. and Kugimiya,A. (2016)
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic
acid-modified gapmer antisense oligonucleotides. Sci. Rep., 6, 30377.
16. Kamola,P.J., Maratou,K., Wilson,P.A., Rush,K., Mullaney,T.,
McKevitt,T., Evans,P., Ridings,J., Chowdhury,P., Roulois,A. et al.
(2017) Strategies for in vivo screening and mitigation of
hepatotoxicity associated with antisense drugs.Mol. Ther. Nucleic
Acids, 8, 383–394.
17. Sewing,S., Boess,F., Moisan,A., Bertinetti-Lapatki,C., Minz,T.,
Hedtjaern,M., Tessier,Y., Schuler,F., Singer,T. and Roth,A.B. (2016)
Establishment of a predictive in vitro assay for assessment of the
hepatotoxic potential of oligonucleotide drugs. PLoS One, 11,
e0159431.
18. Dieckmann,A., Hagedorn,P.H., Burki,Y., Bru¨gmann,C., Berrera,M.,
Ebeling,M., Singer,T. and Schuler,F. (2018) A sensitive in vitro
approach to assess the Hybridization-Dependent toxic potential of
high affinity gapmer oligonucleotides.Mol. Ther. Nucleic Acids, 10,
45–54.
19. Sun,H., Samarghandi,A., Zhang,N., Yao,Z., Xiong,M. and
Teng,B.-B. (2012) Proprotein convertase Subtilisin/Kexin type 9
interacts with apolipoprotein B and prevents its intracellular
degradation, irrespective of the Low-Density lipoprotein receptor.
Arterioscler. Thromb. Vasc. Biol., 32, 1585–1595.
20. Cunningham,F., Amode,M.R., Barrell,D., Beal,K., Billis,K.,
Brent,S., Carvalho-Silva,D., Clapham,P., Coates,G., Fitzgerald,S.
et al. (2015) Ensembl 2015. Nucleic Acids Res., 43, D662–D669.
21. Irizarry,R.A., Hobbs,B., Collin,F., Beazer-Barclay,Y.D.,
Antonellis,K.J., Scherf,U. and Speed,T.P. (2003) Exploration,
normalization, and summaries of high density oligonucleotide array
probe level data. Biostatistics, 4, 249–264.
22. Ritz,C., Baty,F., Streibig,J.C. and Gerhard,D. (2015) Dose-response
analysis using R. PLoS One, 10, e0146021.
23. Smyth,G.K. (2004) Linear models and empirical bayes methods for
assessing differential expression in microarray experiments. Stat.
Appl. Genet. Mol. Biol., 3, Article 3.
24. Benjamini,Y. and Hochberg,Y. (1995) Controlling the false discovery
rate: a practical and powerful approach to multiple testing. J. R.
Statist. Soc. B, 57, 289–300.
25. Hofacker,I.L., Fontana,W., Stadler,P.F., Bonhoeffer,L.S., Tacker,M.
and Schuster,P. (1994) Fast folding and comparison of RNA
secondary structures.Monatsh. Chem., 125, 167–188.
26. SantaLucia,J. and Hicks,D. (2004) The thermodynamics of DNA
structural motifs. Annu. Rev. Biophys. Biomol. Struct., 33, 415–440.
27. Rehmsmeier,M., Steffen,P., Hochsmann,M. and Giegerich,R. (2004)
Fast and effective prediction of microRNA/target duplexes. RNA, 10,
1507–1517.
28. Bondensgaard,K., Petersen,M., Singh,S.K., Rajwanshi,V.K.,
Kumar,R., Wengel,J. and Jacobsen,J.P. (2000) Structural studies of
LNA:RNA duplexes by NMR: conformations and implications for
RNase H activity. Chemistry, 6, 2687–2695.
29. Durbin,R., Eddy,S.R., Krogh,A. and Mitchison,G. (1998) Biological
Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids
1st edn. Cambridge University Press, Cambridge.
30. Lindholm,M.W., Elme´n,J., Fisker,N., Hansen,H.F., Persson,R.,
Møller,M.R., Rosenbohm,C., Ørum,H., Straarup,E.M. and Koch,T.
5380 Nucleic Acids Research, 2018, Vol. 46, No. 11
(2012) PCSK9 LNA antisense oligonucleotides induce sustained
reduction of LDL cholesterol in nonhuman primates.Mol. Ther., 20,
376–381.
31. Braendli-Baiocco,A., Festag,M., Dumong Erichsen,K., Persson,R.,
Mihatsch,M.J., Fisker,N., Funk,J., Mohr,S., Constien,R., Ploix,C.
et al. (2017) From the cover: The minipig is a suitable Non-Rodent
model in the safety assessment of single stranded oligonucleotides.
Toxicol. Sci., 157, 112–128.
32. Straarup,E.M., Fisker,N., Hedtja¨rn,M., Lindholm,M.W.,
Rosenbohm,C., Aarup,V., Hansen,H.F., Ørum,H., Hansen,J.B.R. and
Koch,T. (2010) Short locked nucleic acid antisense oligonucleotides
potently reduce apolipoprotein B mRNA and serum cholesterol in
mice and non-human primates. Nucleic Acids Res., 38, 7100–7111.
33. Elme´n,J., Lindow,M., Silahtaroglu,A., Bak,M., Christensen,M.,
Lind-Thomsen,A., Hedtja¨rn,M., Hansen,J.B., Hansen,H.F.,
Straarup,E.M. et al. (2008) Antagonism of microRNA-122 in mice by
systemically administered LNA-antimiR leads to up-regulation of a
large set of predicted target mRNAs in the liver. Nucleic Acids Res.,
36, 1153–1162.
34. Swayze,E.E., Siwkowski,A.M., Wancewicz,E.V., Migawa,M.T.,
Wyrzykiewicz,T.K., Hung,G., Monia,B.P. and Bennett,C.F. (2007)
Antisense oligonucleotides containing locked nucleic acid improve
potency but cause significant hepatotoxicity in animals. Nucleic Acids
Res., 35, 687–700.
35. Hagedorn,P.H., Yakimov,V., Ottosen,S., Kammler,S., Nielsen,N.F.,
Høg,A.M., Hedtja¨rn,M., Meldgaard,M., Møller,M.R., Ørum,H.
et al. (2013) Hepatotoxic potential of therapeutic oligonucleotides
can be predicted from their sequence and modification pattern.
Nucleic Acid Ther., 23, 302–310.
36. Imming,P., Sinning,C. and Meyer,A. (2006) Drugs, their targets and
the nature and number of drug targets. Nat. Rev. Drug Discov., 5,
821–834.
37. Lindow,M., Vornlocher,H.-P., Riley,D., Kornbrust,D.J., Burchard,J.,
Whiteley,L.O., Kamens,J., Thompson,J.D., Nochur,S., Younis,H.
et al. (2012) Assessing unintended hybridization-induced biological
effects of oligonucleotides. Nat. Biotechnol., 30, 920–923.
38. Stein,C.A. (2001) The experimental use of antisense oligonucleotides:
a guide for the perplexed. J. Clin. Invest., 108, 641–644.
39. Pedersen,L., Hagedorn,P.H., Lindholm,M.W. and Lindow,M. (2014)
A kinetic model explains why shorter and less affine
enzyme-recruiting oligonucleotides can be more potent.Mol. Ther.
Nucleic Acids, 3, e149.
40. Lima,W.F., Vickers,T.A., Nichols,J., Li,C. and Crooke,S.T. (2014)
Defining the factors that contribute to on-target specificity of
antisense oligonucleotides. PLoS One, 9, e101752.
41. Soutschek,J., Akinc,A., Bramlage,B., Charisse,K., Constien,R.,
Donoghue,M., Elbashir,S., Geick,A., Hadwiger,P., Harborth,J. et al.
(2004) Therapeutic silencing of an endogenous gene by systemic
administration of modified siRNAs. Nature, 432, 173–178.
42. Yamamoto,T., Fujii,N., Yasuhara,H., Wada,S., Wada,F.,
Shigesada,N., Harada-Shiba,M. and Obika,S. (2014) Evaluation of
multiple-turnover capability of locked nucleic acid antisense
oligonucleotides in cell-free RNase H-mediated antisense reaction
and in mice. Nucleic Acid Ther., 24, 283–290.
